{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:17Z","timestamp":1761870677320,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.clml.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T21:17:13Z","timestamp":1412371033000},"page":"199-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized Controlled Trials in Relapsed\/Refractory Chronic Lymphocytic Leukemia: A\u00a0Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"15","author":[{"given":"Rachel L.","family":"Police","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Trask","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahnaz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeline","family":"Abbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Colosia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annete","family":"Njue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Sherrill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Ruiz-Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.09.008_bib1","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer Statistics Review: 1975-2010. Available at: http:\/\/seer.cancer.gov\/archive\/csr\/1975_2010\/results_merged\/sect_13_leukemia.pdf. Accessed November 21,\u00a02013."},{"key":"10.1016\/j.clml.2014.09.008_bib2","unstructured":"American Cancer Society. What are the key statistics for chronic lymphocytic leukemia? Available at: http:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/Guide-to-the-single-technology-appraisal-process.pdf. Accessed May 14,\u00a02014."},{"key":"10.1016\/j.clml.2014.09.008_bib3","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CMAR.S34273","article-title":"Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies","volume":"5","author":"Chao","year":"2013","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2014.09.008_bib5","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.09.008_bib6","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1586\/era.11.118","article-title":"Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial","volume":"11","author":"Molica","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2014.09.008_bib7","unstructured":"NICE. National Institute for Health and Care Excellence. Specification for manufacturer\/sponsor submission of evidence. Available at: http:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/Guide-to-the-single-technology-appraisal-process.pdf. Accessed March 20,\u00a02013."},{"key":"10.1016\/j.clml.2014.09.008_bib8","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. Available at: http:\/\/www.york.ac.uk\/inst\/crd\/pdf\/Systematic_Reviews.pdf. Accessed March 20,\u00a02013."},{"key":"10.1016\/j.clml.2014.09.008_bib9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2014.09.008_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2000.01850.x","article-title":"Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients","volume":"108","author":"Robak","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.008_bib11","first-page":"994","article-title":"The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil","volume":"90","author":"Robak","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.09.008_bib12","unstructured":"Clinicaltrials.gov [Web site]. Efficacy and safety of ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia (CLL). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00802737?term=NCT00802737&rank=1. Accessed July\u00a017, 2013."},{"key":"10.1016\/j.clml.2014.09.008_bib13","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O'Brien","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib14","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1470-2045(11)70242-X","article-title":"Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial","volume":"12","author":"Elter","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cncr.22097","article-title":"Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"107","author":"Faderl","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.09.008_bib16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2141.2010.08317.x","article-title":"A\u00a0randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia","volume":"152","author":"Hillmen","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.008_bib17","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","article-title":"Five-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen","volume":"27","author":"O'Brien","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib18","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib19","doi-asserted-by":"crossref","unstructured":"Wendtner C, Fraser G, Goldberg S, et\u00a0al. Interim results for the safety and efficacy of different lenalidomide starting dose regimens in subjects with relapsed or refractory chronic lymphocytic leukemia (CC-5013-CLL-009 Study). Presented at the 2011 ASH annual meeting; December 11, 2011. San Diego, CA.","DOI":"10.1182\/blood.V118.21.2859.2859"},{"key":"10.1016\/j.clml.2014.09.008_bib20","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.008_bib21","unstructured":"FDA. US Food and Drug Administration. FDA News Release: FDA approves Imbruvica to treat chronic lymphocytic leukemia. Available at: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm385764.htm. Accessed May 16,\u00a02014."},{"key":"10.1016\/j.clml.2014.09.008_bib22","unstructured":"Gilead Sciences. US FDA Accepts New Drug Application for Gilead's Idelalisib for\u00a0the Treatment of Refractory Indolent Non-Hodgkin's Lymphoma. Available at:\u00a0http:\/\/www.gilead.com\/news\/press-releases\/2014\/1\/us-fda-accepts-new-drug-application-for-gileads-idelalisib-for-the-treatment-of-refractory-indolent-nonhodgkins-lymphoma. Accessed May 16,\u00a02014."},{"issue":"suppl 6","key":"10.1016\/j.clml.2014.09.008_bib23","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdr377","article-title":"Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Eichhorst","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib24","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib25","doi-asserted-by":"crossref","unstructured":"Brown JR, Furman RR, Flinn I, et\u00a0al. Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3K\u03b4, in patients with relapsed or refractory CLL. Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2013. Chicago, IL.","DOI":"10.1200\/jco.2013.31.15_suppl.7003"},{"key":"10.1016\/j.clml.2014.09.008_bib26","doi-asserted-by":"crossref","unstructured":"Salles GA, Gopal AK, Martin P, et\u00a0al. An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma. Presented at the Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2013. Chicago, IL.","DOI":"10.1200\/jco.2013.31.15_suppl.tps8614"},{"key":"10.1016\/j.clml.2014.09.008_bib27","doi-asserted-by":"crossref","unstructured":"Byrd JC, Barrientos JC, Devereux S, et\u00a0al. A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): RESONATE. Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2013. Chicago, IL.","DOI":"10.1200\/jco.2013.31.15_suppl.tps8619"},{"key":"10.1016\/j.clml.2014.09.008_bib28","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.18_suppl.lba7008","article-title":"Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase III RESONATE trial","volume":"32","author":"Byrd","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib29","doi-asserted-by":"crossref","unstructured":"Flynn JM, Andritsos LA, Jones JA, et\u00a0al. Dinaciclib (SCH 727965) is a novel cyclin-dependent kinase (CDK) inhibitor that exhibits activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Presented at the 55th ASH Annual Meeting and Exposition, December 4-10,\u00a02013. New Orleans, LA.","DOI":"10.1182\/blood.V122.21.871.871"},{"key":"10.1016\/j.clml.2014.09.008_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.3028","article-title":"Phase 2 open-lable study of MEDI-551 and bendamustine versus rituximab and bendamusting in adults with relapsed or refractory CLL","volume":"32","author":"Gladstone","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib31","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.7007","article-title":"Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia","volume":"32","author":"Sharman","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.008_bib32","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.7015","article-title":"ABT-199 (GDC-0199) in relapsed\/refractory (R\/R) chronic lymphocytic keukemia (CLL) and small lymphocytic lymphoma (SLL): high complete-response rate and durable disease control","volume":"32","author":"Seymour","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:25Z","timestamp":1761870385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014004182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S2152265014004182"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.09.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Controlled Trials in Relapsed\/Refractory Chronic Lymphocytic Leukemia: A\u00a0Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}